142 related articles for article (PubMed ID: 36464853)
1. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.
Taylor MH; Leboulleux S; Panaseykin Y; Konda B; de La Fouchardiere C; Hughes BGM; Gianoukakis AG; Park YJ; Romanov I; Krzyzanowska MK; Garbinsky D; Sherif B; Pan JJ; Binder TA; Sauter N; Xie R; Brose MS
Cancer Med; 2023 Feb; 12(4):4332-4342. PubMed ID: 36464853
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
5. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M
Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132
[TBL] [Abstract][Full Text] [Related]
6. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
7. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
11. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
[TBL] [Abstract][Full Text] [Related]
12. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
13. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
[TBL] [Abstract][Full Text] [Related]
14. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
15. Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients.
Fukuda N; Toda K; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2021 Jun; 68(6):639-647. PubMed ID: 33504716
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Bergerot C; Young Rha S; Pal S; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Lyun Lee J; Sunela K; Ciuleanu T; Heng D; Glen H; Wang J; Bennett L; Pan J; O'Hara K; Puente J
Oncologist; 2023 Jan; 28(1):59-71. PubMed ID: 35881028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
